Vertex Pharmaceuticals Stock Today

VRTX Stock  USD 417.32  1.14  0.27%   

Performance

2 of 100

 
Low
 
High
Weak

Odds Of Distress

Less than 1

 
100  
 
Zero
Very Small
Vertex Pharmaceuticals is trading at 417.32 as of the 28th of March 2024; that is -0.27% down since the beginning of the trading day. The stock's open price was 418.46. Vertex Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Vertex Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of July 1991
Category
Healthcare
Classification
Health Care
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 258.31 M outstanding shares of which 4.13 M shares are at this time shorted by private and institutional investors with about 2.57 trading days to cover. More on Vertex Pharmaceuticals

Moving against Vertex Stock

  0.66DNLI Denali Therapeutics Financial Report 13th of May 2024 PairCorr
  0.52CVS CVS Health Corp Financial Report 1st of May 2024 PairCorr
  0.44MESO Mesoblast TrendingPairCorr
  0.43YS YS Biopharma Report 22nd of April 2024 PairCorr

Vertex Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vertex Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.
Environment Score
Governance Score
Social Score
President CEOMD FASN
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Biotechnology, ARCA Biotechnology, Nasdaq 100, Dow Jones Biotechnology, NASDAQ 100 Pre, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Analysts covering Vertex Pharmaceuticals report their recommendations after researching Vertex Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Vertex Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Vertex Pharmaceuticals. The Vertex consensus assessment is calculated by taking the average forecast from all of the analysts covering Vertex Pharmaceuticals.
Financial Strength
Based on the key indicators related to Vertex Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Vertex Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in April. Financial strength of Vertex Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.250.4329
Way Down
Very volatile
Gross Profit Margin1.090.8717
Significantly Up
Slightly volatile
Total Current Liabilities3.7 B3.5 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total1.7 B1.6 B
Sufficiently Up
Slightly volatile
Total Assets23.9 B22.7 B
Sufficiently Up
Slightly volatile
Total Current Assets14.9 B14.1 B
Sufficiently Up
Slightly volatile
Vertex Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vertex Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vertex Pharmaceuticals' financial leverage. It provides some insight into what part of Vertex Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Vertex Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Vertex Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Vertex Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 808.4 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 4.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vertex Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

End Period Cash Flow

10.89 Billion
Vertex Pharmaceuticals (VRTX) is traded on NASDAQ Exchange in USA. It is located in 50 Northern Avenue, Boston, MA, United States, 02210 and employs 5,400 people. Vertex Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 108.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vertex Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 258.31 M outstanding shares of which 4.13 M shares are at this time shorted by private and institutional investors with about 2.57 trading days to cover. Vertex Pharmaceuticals currently holds about 9.77 B in cash with 3.54 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Vertex Pharmaceuticals maintains a total of 258.31 Million outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Vertex Ownership Details

Vertex Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Vertex Pharmaceuticals jumping above the current price in 90 days from now is about 65.51%. The Vertex Pharmaceuticals probability density function shows the probability of Vertex Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Vertex Pharmaceuticals has a beta of 0.5507. This entails as returns on the market go up, Vertex Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Vertex Pharmaceuticals will be expected to be much smaller as well. Additionally, vertex Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 417.32HorizonTargetOdds Above 417.32
34.07%90 days
 417.32 
65.51%
Based on a normal probability distribution, the odds of Vertex Pharmaceuticals to move above the current price in 90 days from now is about 65.51 (This Vertex Pharmaceuticals probability density function shows the probability of Vertex Stock to fall within a particular range of prices over 90 days) .

Vertex Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.
InstituionRecorded OnShares
Massachusetts Financial Services Company2023-12-31
3.6 M
Capital Research Global Investors2023-12-31
3.6 M
Loomis, Sayles & Company Lp2023-12-31
3.1 M
Norges Bank2023-12-31
M
Morgan Stanley - Brokerage Accounts2023-12-31
M
Goldman Sachs Group Inc2023-12-31
M
Amundi2023-12-31
2.7 M
Northern Trust Corp2023-12-31
2.7 M
Ubs Asset Mgmt Americas Inc2023-12-31
2.6 M
Vanguard Group Inc2023-12-31
22.3 M
Blackrock Inc2023-12-31
21.9 M
View Vertex Pharmaceuticals Diagnostics

Vertex Pharmaceuticals Historical Income Statement

Vertex Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Vertex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vertex Pharmaceuticals revenue and expense. Vertex Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024. View More Fundamentals

Vertex Stock Against Markets

Picking the right benchmark for Vertex Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vertex Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vertex Pharmaceuticals is critical whether you are bullish or bearish towards Vertex Pharmaceuticals at a given time. Please also check how Vertex Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Vertex Pharmaceuticals Corporate Directors

Vertex Pharmaceuticals corporate directors refer to members of a Vertex Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Vertex Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Vertex Pharmaceuticals' board members must vote for the resolution. The Vertex Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
William YoungIndependent DirectorProfile
Alan GarberIndependent DirectorProfile
Margaret McGlynnIndependent DirectorProfile
Sangeeta BhatiaDirectorProfile

How to buy Vertex Stock?

Before investing in Vertex Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Vertex Pharmaceuticals. To buy Vertex Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Vertex Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Vertex Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Vertex Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Vertex Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Vertex Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Already Invested in Vertex Pharmaceuticals?

The danger of trading Vertex Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vertex Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vertex Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vertex Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.181
Earnings Share
13.89
Revenue Per Share
38.297
Quarterly Revenue Growth
0.093
Return On Assets
0.1317
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.